EDIT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Editas Medicine Inc (EDIT) is not a strong buy for a beginner investor with a long-term strategy at this time. While there are some positive indicators such as hedge fund buying and a significant revenue increase in the latest quarter, the stock's technical indicators suggest it is overbought, and the financial performance shows a concerning decline in net income and EPS. Additionally, there are no recent news catalysts or strong proprietary trading signals to support a buy decision.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 80.468, signaling the stock is overbought. Moving averages are converging, suggesting indecision in the trend. The stock is trading near resistance levels (R1: 2.184), which could limit further upside in the short term.
Hedge funds are significantly increasing their positions, with a 500.44% increase in buying over the last quarter. Revenue surged by 12,265.57% YoY in Q3 2025.
The stock is overbought based on RSI, and there are no recent news catalysts. Financial performance shows a sharp decline in net income (-59.58% YoY) and EPS (-62.67% YoY). No recent congress trading data or influential figure activity.
In Q3 2025, revenue increased significantly to $7.54M (+12,265.57% YoY), but net income dropped to -$25.12M (-59.58% YoY), and EPS fell to -$0.28 (-62.67% YoY). Gross margin remained stable at 100%.
No recent analyst rating or price target changes available for review.
